Mark Loeb, ACC 2022: IVVE: Randomized controlled trial of influenza vaccine in patients with heart failure to reduce adverse vascular events
The IVVE study is a randomized controlled trial of influenza vaccine in patients with heart failure to reduce adverse vascular events. It was delightful to speak with Prof Mark Loeb (McMaster University, Hamilton, Canada) about his presentation at the American College of Cardiology Annual Meeting 2022.
Questions:
- What is known about the effects of the influenza vaccine on mortality and cardiovascular outcomes in patients with heart failure? (00:22)
- What were the aims and design of the IVVE study? (01:22)
- What were the primary outcome findings of the study? (03:00)
- Were any other variables found to modify the benefits of vaccination? (04:36)
- On the basis of these findings, what are your recommendations for future clinical practice? (05:15)
Disclosures: Mark Loeb discloses grant/research support from CIHR, WHO and Seqirus.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.
Filmed in coverage of the American College of Cardiology Annual Meeting 2022
